Enhancing Oral Bioavailability of DMT with a Proprietary Reversible Monoamine Oxidase Inhibitor (RIMA) for Alcohol Use Disorder Therapy
About This Grant
PROJECT SUMMARY Alcohol use disorder (AUD) represents a significant public health crisis in the U.S, affecting over 10% of the population above the age of 12. Despite its prevalence, only 8% of AUD patients receive any treatment, with only 2% receiving pharmaceutical interventions. Current standard treatments, including cognitive-behavioral therapy, naltrexone, acamprosate, and disulfiram, demonstrate limited efficacy and unacceptably high relapse rates. This substantial treatment gap highlights the urgent need for novel therapeutic approaches. Emerging research suggests serotonergic psychedelics, including dimethyltryptamine (DMT), show promise in treating addiction with larger and longer-lasting effects than conventional treatments. Compared to LSD and psilocybin, DMT offers distinct advantages over other psychedelics, including higher efficacy for activation of intracellular 5- HT2A, tolerance development with repeated use, and potentially the strongest subjective experience. This makes DMT particularly suitable for regular dosing regimens and suggests significant potential for therapeutic applications. However, DMT faces significant pharmacokinetic challenges when administered orally. It is rapidly degraded by monoamine oxidase (MAO), resulting in no psychotropic effects and extensive conversion to inactive metabolites. This necessitates alternative administration routes like inhalation or infusion, which introduce variability or patient distress. Remedi Inc. is pioneering an innovative approach by co-formulating DMT with CX157, a proprietary reversible and selective MAO-A inhibitor (RIMA). Unlike irreversible MAOIs, CX157 reversibly inhibits MAO-A, mitigating serious side effect risks. CX157's selectivity for MAO-A over MAO-B also improves tolerability. Additionally, this co-formulation reduces abuse potential, as CX157 creates subjectively unpleasant side effects at high doses. Unlike harmine, a commonly used MAOI, CX157 is not a P450 substrate, reducing pharmacokinetic variability across patients. Preliminary data also demonstrates that CX157 is consistently reversible, enabling recovery of MAO activity within 12 hours in humans. This Phase I project aims to demonstrate feasibility for this oral combination therapeutic approach through 1) demonstrating CX157 enables oral bioavailability in a rat model, where comprehensive pharmacokinetic profiles will be characterized. This study will also include quantification of the head twitch response (HTR). 2) Demonstrate efficacy in reducing ethanol consumption in a validated rat model of AUD and characterize synaptogenesis in rats orally administered CX157/DMT. Success metrics include achieving appropriate pharmacokinetic parameters and significant reduction in alcohol consumption in animal models. Commercialization of this DMT/CX157 product could transform AUD treatment by providing the first orally bioavailable administration of DMT with stable consistent dosing and a strong safety profile. Success with this novel approach has the potential to significantly impact public health by addressing the substantial unmet need in AUD treatment.
Grant Summary
Enhancing Oral Bioavailability of DMT with a Proprietary Reversible Monoamine Oxidase Inhibitor (RIMA) for Alcohol Use Disorder Therapy is a NIAAA - National Institute on Alcohol Abuse and Alcoholism grant providing up to $294K for university, nonprofit, healthcare org. Applications are due 2027-06-30 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $294K
2027-06-30
- 1Confirm your organization is eligible for Enhancing Oral Bioavailability of DMT with a Proprietary Reversible Monoamine Oxidase Inhibitor (RIMA) for Alcohol Use Disorder Therapy from NIAAA - National Institute on Alcohol Abuse and Alcoholism, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAAA - National Institute on Alcohol Abuse and Alcoholism before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAAA - National Institute on Alcohol Abuse and Alcoholism's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Enhancing Oral Bioavailability of DMT with a Proprietary Reversible Monoamine Oxidase Inhibitor (RIMA) for Alcohol Use Disorder Therapy: Frequently Asked Questions
Who is eligible for the Enhancing Oral Bioavailability of DMT with a Proprietary Reversible Monoamine Oxidase Inhibitor (RIMA) for Alcohol Use Disorder Therapy?
Enhancing Oral Bioavailability of DMT with a Proprietary Reversible Monoamine Oxidase Inhibitor (RIMA) for Alcohol Use Disorder Therapy is offered by NIAAA - National Institute on Alcohol Abuse and Alcoholism and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Enhancing Oral Bioavailability of DMT with a Proprietary Reversible Monoamine Oxidase Inhibitor (RIMA) for Alcohol Use Disorder Therapy provide?
Enhancing Oral Bioavailability of DMT with a Proprietary Reversible Monoamine Oxidase Inhibitor (RIMA) for Alcohol Use Disorder Therapy provides up to $294K per award from NIAAA - National Institute on Alcohol Abuse and Alcoholism. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Enhancing Oral Bioavailability of DMT with a Proprietary Reversible Monoamine Oxidase Inhibitor (RIMA) for Alcohol Use Disorder Therapy deadline?
Applications for Enhancing Oral Bioavailability of DMT with a Proprietary Reversible Monoamine Oxidase Inhibitor (RIMA) for Alcohol Use Disorder Therapy are due 2027-06-30 (open). Because deadlines can change, verify the date with the funder, NIAAA - National Institute on Alcohol Abuse and Alcoholism, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Enhancing Oral Bioavailability of DMT with a Proprietary Reversible Monoamine Oxidase Inhibitor (RIMA) for Alcohol Use Disorder Therapy?
To apply for Enhancing Oral Bioavailability of DMT with a Proprietary Reversible Monoamine Oxidase Inhibitor (RIMA) for Alcohol Use Disorder Therapy, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAAA - National Institute on Alcohol Abuse and Alcoholism.